Clinical trials: Eye Cancer, Intraocular Melanoma
Uveal Melanoma
Vascular Response to Brachytherapy Using Functional OCT
The purpose of this study is to learn how blood flows to tumors in patients treated with I-125 plaque brachytherapy for uveal melanoma.
- Trial name
- NCT01955941
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- OHSU Knight Cancer Institute
Uveal Melanoma
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib…
- Trial name
- NCT02223819
- Testing
- Crizotinib
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Columbia University
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has…
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension
- Trial name
- NCT01989572
- Testing
- Laboratory Biomarker Analysis, Sargramostim, Tyrosinase Peptide
- Where
- 148 sites in United States
- Volunteers
- 815 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Metastatic Uveal Melanoma in the Liver
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
- Trial name
- NCT04935229
- Testing
- SD-101, Nivolumab, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- TriSalus Life Sciences, Inc.
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
- Trial name
- NCT01100528
- Testing
- recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Case Comprehensive Cancer Center
Melanoma, Uveal Neoplasms
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
A randomized controlled, open-label, multi-centre study evaluating if Isolated Hepatic Perfusion (IHP) increases Overall Survival compared with Best Alternative Care (BAC) in patients with isolated liver metastases from uveal…
- Trial name
- SCANDIUM (NCT01785316)
- Testing
- IHP
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Vastra Gotaland Region
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT01413191
- Testing
- Cixutumumab, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been…
- Trial name
- NCT06581406
- Testing
- RP2, Ipilimumab, Nivolumab
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 280 people
- Sponsor
- Replimune, Inc.
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Uveal Melanoma, Ocular Melanoma
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
- Trial name
- NCT05524935
- Testing
- Pembrolizumab, Olaparib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ocular Melanoma
Eye Plaque Brachytherapy for Ocular Melanoma
This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes.
- Trial name
- PROMPT (NCT06432660)
- Testing
- Data collection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Choroidal Melanoma
Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)
Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma
- Trial name
- ctDNA MU (NCT02875652)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Institut Curie
Uveal Melanoma
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
This is a Phase 2, multi-center, open-label study in patients with surgically incurable stage III or IV uveal melanoma who have not received prior immunotherapy.
- Trial name
- NCT01034787
- Testing
- CP-675,206
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- AHS Cancer Control Alberta
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body.
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma
- Trial name
- NCT01143402
- Testing
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 33 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming…
- Trial name
- NCT00032045
- Testing
- gp100 antigen, incomplete Freund's adjuvant, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Radiation Retinopathy, Choroidal Melanoma
Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
This is a Phase I clinical trial to test the safety and tolerability of intravitreal ranibizumab in the treatment of radiation retinopathy following plaque brachytherapy for patients with choroidal melanoma using the incidence…
- Trial name
- NCT00750399
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The New York Eye Cancer Center
Choroidal Melanoma, Indeterminate Lesions
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to…
- Trial name
- IL (NCT05266430)
- Testing
- Standard of Care, AU-011
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Aura Biosciences
Intraocular Melanoma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00738361
- Testing
- nab-paclitaxel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ohio State University Comprehensive Cancer Center